blood-brain barrier

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model

Natalizumab and Tyruko in Multiple Sclerosis Therapy Natalizumab is a monoclonal antibody that targets the alpha-4 integrin subunit, inhibiting the

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model Read Post »

Scroll to Top